Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors
Authors:
Open Access
- 10 January 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 781425
Abstract
Lung cancer is one of the malignant tumors that has seen the most rapid growth in terms of morbidity and mortality in recent years, posing the biggest threat to people’s health and lives. In recent years, the nano-drug loading system has made significant progress in the detection, diagnosis, and treatment of lung cancer. Nanomaterials are used to specifically target tumor tissue to minimize therapeutic adverse effects and increase bioavailability. It is achieved primarily through two mechanisms: passive targeting, which entails the use of enhanced penetration and retention (EPR) effect, and active targeting, which entails the loading recognition ligands for tumor marker molecules onto nanomaterials. However, it has been demonstrated that the EPR effect is effective in rodents but not in humans. Taking this into consideration, researchers paid significant attention to the active targeting nano-drug loading system. Additionally, it has been demonstrated to have a higher affinity and specificity for tumor cells. In this review, it describes the development of research into active targeted nano-drug delivery systems for lung cancer treatment from the receptors’ or targets’ perspective. We anticipate that this study will help biomedical researchers use nanoparticles (NPs) to treat lung cancer by providing more and novel drug delivery strategies or solid ligands.Keywords
This publication has 109 references indexed in Scilit:
- A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cellsCell Death & Disease, 2013
- Tumor Targeting via Integrin LigandsFrontiers in Oncology, 2013
- Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: Development and characterizationJournal of Drug Targeting, 2012
- Nanoparticle delivery of a peptide targeting EGFR signalingJournal of Controlled Release, 2012
- Tumor Specific Delivery and Therapy by Double-Targeted Nanostructured Lipid Carriers with Anti-VEGFR-2 AntibodyMolecular Pharmaceutics, 2011
- Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer, 2010
- Identification of uPAR-positive Chemoresistant Cells in Small Cell Lung CancerPLOS ONE, 2007
- Block copolymer micelles: preparation, characterization and application in drug deliveryJournal of Controlled Release, 2005
- Angiogenesis and Lung Cancer: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2005
- MECHANISMS OF PHAGOCYTOSIS IN MACROPHAGESAnnual Review of Immunology, 1999